Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension

Current Hypertension Reports

Volumn 15, Issue 5, 2013, Pages 475-483

  Chrysant, Steven G ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

CAD; Coronary artery disease; Diabetes mellitus; Heart failure; Hypertension; PDE 5 inhibitors; Pulmonary hypertension; Raynaud's phenomenon

Indexed keywords

NITRATE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; PENIS ERECTION; PLEIOTROPY; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYPERTENSION; PHOSPHODIESTERASE 5 INHIBITORS; TREATMENT OUTCOME;

EID: 84893687227     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0377-9     Document Type: Article

References (75)

1. Conti M, Jin SL. The molecular biology of cyclic nucleoside phosphodiesterases. Prog Nucleic Acid Res Mol Biol. 1999;63:1-38.
2. Stacey P, Rulten S, Darling A, Phillips SC. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE 5). Biochem Biophys Res Commun. 1998;247:249-54.
3. Sasaki T, Kotera J, Yuasa K, Omori K. Identification of human PDE 7B a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun. 2000;271:575-83.
4. Fisher DA, Smith JF, Pillar JS, St Dennis SH, Cheng JB. Isolation and characterization of PDE 8A, a novel human cAMP-specific posphodiesterase. Biochem Biophys Res Commun. 1998;246:570-7.
5. Fisher DA, Smith JF, Pillar JS, St Dennis SH, Cheng JB. Isolation and characterization of PDE 9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 1998;273:15559-64.
6. Soderling SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual substrate phosphodiesterase gene family: PDE 10A. Proc Natl Acad Sci U S A. 1999;96:7071-6.
7. Yuasa K, Kotera J, Fujishige K, et al. Isolation and characterization of two novel phosphodiesterase PDE 11Avariants showing unique structure and tissue-specific expression. J Biophys Chem. 2000;275:31469-79.
8. Reffelman T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation. 2003;108:239-44.
9. Senzaki H, Smith CJ, Juang CJ, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates b-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. 2001;15:1718-26.
10. Zusman RM. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Am J Cardiol. 1999;83:1C-2C.
11. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and contractile responses of rabecuae carnie and aortic rings in vitro. Am J Cardiol. 1999;83:3C-12C.
12. Fink HA, MacDonald R, Rutks IR, et al. Sildenafil for male erectile dysfunction: a systemic review and meta-analysis. Arch Intern Med. 2002;162:1349-60.
13. Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002;23:763-71.
14. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332-6.
15. Cheitlin MD, Hutter AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol. 1999;33:273-82.
16. Mathers CD, Boerma T, Ma Fat D. Global and regional causes of death. Br Med Bull. 2009;92:7-32.
17. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294:2996-3002.
18. Billups KL, Bank AJ, Padma-Nathan H, Katz S, Williams R. Erectile dysfunction is a marker for cardiovascular disease: results of the Minority Health Institute Expert Advisory Panel. J Sex Med. 2005;2:40-50.
19. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004;110:3149-55.
20. Jamnicki-Abegg M, Weihrauch D, Chiari PC, et al. Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-1 expression and cardioprotection. J Cardiovasc Pharmacol. 2007;50:670-6.
21. Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effects via opening of mitochondrial channels in rabbits. Am J Physiol Heart Circ Physiol. 2002;283: H 1263-9.
22. Wang X, Fisher PW, Xi L, Kukreja RC. Essential role of mitochondrial Ca2+ activated and ATP-sensitive K+ channels in sildenafilinduced late cardioprotection. J Mol Cell Cardiol. 2008;44:105-13.
23. Salloum FN, Abbate A, Das A, et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol. 2008;294: H 1398-406.
24. Madhani M, Hall AR, Cuello F, et al. Phospholemman Ser 69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury. Am J Physiol Heart Circ Physiol. 2010;299:H827-36.
25. Salloum FN, Ockaili RA, Wittkamp M, Marwaha VR, Kukreja RC. Vardenafil a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K (ATP) channels in rabbits. J Mol Cell Cardiol. 2006;40:405-11.
26. Sesti C, Florio V, Johnson EG, Kloner RA. The phosphodiesterase 5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res. 2007;19:55-61.
27. Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA. Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012;59:9-15. A well-written, informed, and concise review on the cardiovascular effects and uses of PDE5 inhibitors.
28. De Busk RF, Pepine CJ, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol. 2004;93:147-253.
29. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002;40:2006-12.
30. Fox KM, Thadani U, Ma TS, et al. Sildenafil citrate does not reduce tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J. 2003;24:2206-12.
31. Herrmann H, Chang G, Klugher BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med. 2000;342:1622-6.
32. Jackson G, Kelta M, Csanady M, et al. Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction. J Sex med. 2005;2:407-14.
33. Papatsoris AG, Karantzopoulos PG. Hypertension, and antihypertensive therapy, and erectile dysfunction. Angiology. 2006;57:47-52.
34. Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep. 2002;4:202-10.
35. Grimm RH, Grandits GA, Prineas RG, et al. Long-term effects on sexual dysfunction of five antihypertensive drugs and nutritional treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29:8-14.
36. Kloner RA, Brown M, Prisant LM, et al. Effects of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Hypertension. 2001;14:70-3.
37. Nera A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both condtions. Mayo Clin Proc. 2009;84:139-48.
38. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients with common antihypertensive therapies. Am J Cardiol. 2003;91(Supp):47M-57M. A well written informed review on the interaction of the 3 PDE 5 inhibitors with antihypertensive drugs in patients with hypertension.
39. Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents. Am J Hypertens. 2004;17:1135-42.
40. Oliver JJ, Dear JW, Webb DJ. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment resistant hypertension. Hypertension. 2010;56:62-7.
41. Lewis GD, Shah R, Shahzal K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-62.
42. Hirata K, Adji A, Vlachopoulos C, et al. Effects of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol. 2005;96:1436-40.
43. Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure. A double-blind, placebo-controlled, randomized study followed by prospective treatment for erectile dysfunction. Circulation. 2002;106:1097-103.
44. Webster LJ, Michelakis ED, Davis T, Archer SL. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association class II and III congestive heart failure. Arch Intern Med. 2004;164:514-20.
45. Lu Z, Xu X, Hu X, et al. Oxidative stress regulates left ventricular PDE 5 expression in the failing heart. Circulation. 2010;121:1474-83.
46. Chau VQ, Shalloum FN, Hoke NN, et al. Mitigation of the progression of heart failure with sildenafil involves inhibition of Rho/Rho-kinase pathway. Am J Physiol Heart Circ Physiol. 2011;300:H2272-9.
47. Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as therapeutic target in heart failure. J Am Coll Cardiol. 2013;61:599-610. A very exciting review on the important role of mitochondria in the function of the heart. Their modulation with PDE 5 inhibitors to improve myocardial contractility in patients with heart failure.
48. Garesse R, Vallejo CG. Animalmitochondria biogenesis and function: a regulatory cross-talk between two genomes. Gene. 2001;263:1-16.
49. Clementi E, Nisoli E. Nitric oxide and mitochondrial biogenesis: a key to long-term regulation of cellular metabolism. Comp Biochem Physiol A Mol Integr Physiol. 2005;142:102-10.
50. Brown GC. Nitric oxide and mitochondria. Front Biosci. 2007;12:1024-33.
51. De Toni L, Strapazzon G, Gianesello L. Effects of type 5-phosphodiesterase inhibition on energy metabolism and mitochondrial biogenesis in adipose tissue ex vivo. J Endocrinol Investig. 2011;34:738-41.
52. Cvelich RG, Roberts SC, Brown JN. Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure. Ann Pharmacother. 2011;45:1551-8.
53. Badesch DB, Champion HC, Gomez-Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(Suppl S):S55-60.
54. Waxman AB, Zamanian RT. Pulmonary arterial hypertension: new insights into optimal role of current and emerging prostacyclin therapies. Am J Cardiol. 2013;111 Suppl 5:1A-16A.
55. Vlachopoulos C, Ioakeimidis N, Rokkas K, et al. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med. 2009;6:658-74.
56. Rubin LJ, Badesch DB, Flemming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension. The SUPER-2 Study. Chest. 2011;140:1274-83.
57. Jing ZC, Shen JY, Wu BX, et al. Vardenafil for the treatment of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;183:1723-9.
58. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy in pulmonary arterial hypertension. 2009;119:2894-903.
59. Oudiz RJ, Brundage BH, Galie N, et al. Tadalafil for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2012;60:768-74.
60. Goldstein I, Young JM, Fischer J, Vardenafil Diabetes Study Group, et al. Vardenafil, a new phosphodiesterase 5 inhibitor in the treatment of erectile dysfunction in men with diabetes: a multicenter, double-blind, placebo-controlled, fixed-dose study. Diabetes Care. 2003;26:777-83.
61. Phe V, Roupret M. Erectile dysfunction and diabetes: a review of the current evidence-based medicine and synthesis of the main available therapies. Diabetes Metab. 2012;38:1-13.
62. Angulo J, Gonzalez-Corrochano R, Cuevas P, et al. Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J Sex Med. 2010;7:758-68.
63. Deyoung L, Chung E, Kovacs JR, et al. Daily use of sildenafil improves endothelial function in men with type 2 diabetes. J Androl. 2012;33:176-80.
64. Schneider T, Gleissner J, Merfort F, et al. Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with the metabolic syndrome: results of a randomized, placebo-controlled trial. J Sex Med. 2011;8:2904-11.
65. Hatzichristou D, Gambia M, Rubio-Aurioles E, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008;25:138-46.
66. Grover-Paez F, Villegas Rivera G, Guillen Ortiz R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;78:136-40.
67. Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ. 1990;301:590-2.
68. Wigley FM. Raynaud's phenomenon. N Engl J Med. 2002;347:1001-8.
69. Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud's disease. Arch Intern Med. 2006;166:231-3.
70. Fries R, Shariat K, Von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980-5.
71. Roustit M, Hellmann M, Cracowski C, et al. Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon. Clin Pharmacol Ther. 2012;91:813-9.
72. Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a doubleblind randomized cross-over study. Rheumatology. 2010;49:2420-8.
73. Friedman EA, Harris PA, Wood A J J, et al. The effects of tadalafil on cold-induced vasoconstriction in patients with the Raynaud's phenomenon. Clin Pharmacol Ther. 2007;81:503-9.
74. De La Vega AJ, Derk CT. Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication. Expert Opin Investig Drugs. 2009;18:23-9.
75. Rosenkranz S, Brixius K, Halbach R, et al. Phoshodiesterase type 5 inhibitor sildenafil citrate does not potentiate the vasodilative properties of nebivolol in rat aorta. Life Sci. 2006;78:1103-7.